{"id":"jmt101-injection","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"JMT101 injection works by binding to its target protein, thereby inhibiting its activity and modulating the immune response. This mechanism of action is thought to be beneficial in treating various immune-related disorders.","oneSentence":"JMT101 injection is a monoclonal antibody targeting a specific protein to modulate the immune system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:41.253Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of moderate to severe rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT06989671","phase":"PHASE2","title":"SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-08-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT06892431","phase":"PHASE2","title":"JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-04-01","conditions":"Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy","enrollment":150},{"nctId":"NCT06735391","phase":"PHASE3","title":"A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations","status":"RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2024-10-23","conditions":"Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC, Previously Untreated Systematically NSCLC","enrollment":516},{"nctId":"NCT06391944","phase":"PHASE2","title":"JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2021-11-21","conditions":"Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation","enrollment":161},{"nctId":"NCT06380348","phase":"PHASE3","title":"JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2024-04-26","conditions":"Local Advanced or Metastatic NSCLC","enrollment":398}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recombinant Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Injection","FOLFIRI(Irinotecan, Leucovorin Calcium, and Fluorouracil); mFOLFOX6((Oxaliplatin, Leucovorin Calcium, and Fluorouracil);","FOLFIRI; mFOLFOX6; Irinotecan;","Afatinib or Osimertinib"],"phase":"phase_3","status":"active","brandName":"JMT101 injection","genericName":"JMT101 injection","companyName":"Shanghai JMT-Bio Inc.","companyId":"shanghai-jmt-bio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JMT101 injection is a monoclonal antibody targeting a specific protein to modulate the immune system. Used for Treatment of moderate to severe rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}